Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Doseology Sciences (VU70) AI Stock Analysis

DE:VU70

Doseology Sciences

(Frankfurt:VU70)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Debt-free balance sheetA near-zero debt position and equity cushion materially reduce leverage risk and give the company more financing flexibility over the medium term. This durable strength lowers default risk and supports strategic options (M&A, licensing, or capital raises) while losses persist.
Negative Factors
Persistent operating lossesLarge ongoing operating deficits relative to revenue show the business has not scaled to cover fixed costs. Persistent losses will continue to erode equity, limit reinvestment capacity, and force reliance on external capital unless meaningful margin improvements are achieved.

Doseology Sciences (VU70) vs. iShares MSCI Germany ETF (EWG)

-100%-50%0%50%100%150%200%DE:VU70-88.12%EWG+4.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 680.99K
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-0.6
Beta (1Y)
1.48
Revenue Growth
61.37%
EPS Growth
-94.34%
Country
Germany
Employees
5
Sector
Healthcare
Sector Strength
51
Industry
Medical - Pharmaceuticals

Doseology Sciences Business Overview & Revenue Model

Company Description

Doseology Sciences Inc., through its subsidiary, Dose Labs Inc., engages in the research, development, and sale of functional mushroom products with a focus on mental health research in Canada. The company also offers medicinal mushroom products, inc...

Doseology Sciences Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:VU70 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:DOSETSE:DOSE38UnderperformCAD 14.33M-4.4142.51%―-19.31%34.45%

* Healthcare Sector Average

Performance Comparison

0%100%200%DE:VU70TSE:DOSETSE:MYNDTSE:IBOTSE:MBIODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:VU70 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:VU70Doseology Sciences, Inc.0.02-0.12-83.22%
TSE:DOSERapid Dose Therapeutics Corp0.10-0.06-34.38%
TSE:MYNDMynd Life Sciences Inc0.070.000.00%
TSE:IBOUniversal Ibogaine Inc0.010.000.00%
TSE:MBIOMindbio Therapeutics Corp.0.10-1.90-94.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.